New Study Offers Hope for Type 2 Diabetes Patients Struggling with Weight Loss

The CT-388-104 Study is a clinical trial focused on evaluating the safety and effectiveness of a selective GLP-1/GIP investigational drug for individuals living with overweight or obesity alongside type 2 diabetes. This study is particularly aimed at those who have previously attempted to lose weight through diet and exercise without success.

Eligibility Criteria:

• Age between 18 and 75 years
• Body Mass Index (BMI) of 25 or above
• Diagnosis of type 2 diabetes
• Previous unsuccessful attempts at weight loss through diet and exercise

Participants who qualify for the study may receive:

• The investigational drug or placebo at no cost
• Close medical care and follow-up throughout the study
• Lifestyle management counseling

This study represents a significant opportunity for individuals with type 2 diabetes to explore new avenues for managing their condition and achieving weight loss goals. For more information on how to participate, interested individuals are encouraged to contact the study team directly.